PU4959USw

Amendments to the Claims:

Please amend claim 20 as follows.

1. (Previously Presented) A compound of formula (I):



I

wherein:

p is 0, 1, 2, 3 or 4;

each R^1 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, $-OR^7$, -OAy, $-OR^{10}$Ay, -OHet, $-OR^{10}$Het, $-C(O)R^9$, -C(O)Ay, -C(O)Het, $-CO_2R^9$, $-C(O)NR^7R^8$, $-C(O)NR^7$Ay, $-C(O)NHR^{10}$Ay, $-C(O)NHR^{10}$Het, $-C(S)NR^9R^{11}$, $-C(NH)NR^7R^8$, $-C(NH)NR^7$Ay, $-S(O)_nR^9$, $-S(O)_n$Ay, $-S(O)_n$Het, $-S(O)_2NR^7R^8$, $-S(O)_2NR^7$Ay, $-NR^7R^8$, $-NR^7$Ay, -NHHet, $-NHR^{10}$Ay, $-NHR^{10}$Het, $-R^{10}$cycloalkyl, $-R^{10}$Ay, $-R^{10}$Het, $-R^{10}O-C(O)R^9$, $-R^{10}O-C(O)$Ay, $-R^{10}O-C(O)$Het, $-R^{10}O-S(O)_nR^9$, $-R^{10}OR^9$, $-R^{10}C(O)R^9$, $-R^{10}CO_2R^9$, $-R^{10}C(O)NR^9R^{11}$, $-R^{10}C(O)NR^7$Ay, $-R^{10}C(O)NHR^{10}$Het, $-R^{10}C(S)NR^9R^{11}$, $-R^{10}C(NH)NR^9R^{11}$, $-R^{10}SO_nR^9$, $-R^{10}SO_2NR^9R^{11}$, $-R^{10}SO_2NHCOR^9$, $-R^{10}NR^7R^8$, $-R^{10}NR^7$Ay, $-R^{10}NHC(NH)NR^9R^{11}$, cyano, nitro and azido; or

two adjacent R^1 groups together with the atoms to which they are bonded form a C_{5-6}cycloalkyl or a 5 or 6-membered heterocyclic ring containing 1 or 2 heteroatoms;

each R^7 and R^8 are the same or different and are independently selected from the group consisting of H, alkyl, alkenyl, cycloalkyl, cycloalkenyl, $-C(O)R^9$, $-CO_2R^9$, $-C(O)NR^9R^{11}$, $-C(S)NR^9R^{11}$, $-C(NH)NR^9R^{11}$, $-SO_2R^{10}$, $-SO_2NR^9R^{11}$, $-R^{10}$cycloalkyl, $-R^{10}OR^9$, $-R^{10}C(O)R^9$, $-R^{10}CO_2R^9$, $-R^{10}C(O)NR^9R^{11}$, $-R^{10}C(S)NR^9R^{11}$, $-R^{10}C(NH)NR^9R^{11}$, $-R^{10}SO_2R^{10}$, $-R^{10}SO_2NR^9R^{11}$, $-R^{10}SO_2NHCOR^9$, $-R^{10}NR^9R^{11}$, $-R^{10}NHCOR^9$, $-R^{10}NHSO_2R^9$ and $-R^{10}NHC(NH)NR^9R^{11}$;

each R^9 and R^{11} are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, $-R^{10}$cycloalkyl, $-R^{10}OH$, $-R^{10}(OR^{10})_w$ where w is 1-10, and $-R^{10}NR^{10}R^{10}$;

each R^{10} is the same or different and is independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl;

Ay is aryl;

Het is a 5- or 6-membered heterocyclic or heteroaryl group;

R^2 is selected from the group consisting of halo, alkyl, alkenyl, cycloalkyl, cycloalkenyl, Ay, Het, $-OR^7$, -OAy, -OHet, $-OR^{10}$Het, $-S(O)_nR^9$, $-S(O)_n$Ay, $-S(O)_nNR^7R^8$, $-S(O)_n$Het, $-NR^7R^8$, -NHHet, $-NHR^{10}$Ay, $-NHR^{10}$Het, $-R^{10}NR^7R^8$ and $-R^{10}NR^7$Ay;

n is 0, 1 or 2;

Y is N;

R^3 and R^4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ay, Het, $-OR^7$, -OAy, $-C(O)R^7$, -C(O)Ay, $-CO_2R^7$, $-CO_2$Ay, $-SO_2NHR^9$, $-NR^7R^8$, $-NR^7$Ay, -NHHet, $-NHR^{10}$Het, $-R^{10}$cycloalkyl, $-R^{10}OR^7$, $-R^{10}$OAy, $-R^{10}NR^7R^8$ and $-R^{10}NR^7$Ay;

R^5 is the selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, $-OR^7$, -OAy, -OHet, $-OR^{10}$Ay, $-OR^{10}$Het, $-C(O)R^9$, -C(O)Ay, -C(O)Het, $-CO_2R^8$, $-C(O)NR^7R^8$, $-C(O)NR^7$Ay, $-C(O)NHR^{10}$Het, $-CH(OR^9)_2$, $-CH(OR^9)-R^{10}$, $-CH(OR^9)$-Ay, $-C(S)NR^9R^{11}$, $-C(NH)NR^7R^8$, $-C(NH)NR^7$Ay, $-S(O)_nR^8$, $-S(O)_2NR^7R^8$, $-S(O)_2NR^7$Ay, $-NR^7R^8$, $-NR^7$Ay, -NHHet, $-NHR^{10}$Ay, $-NHR^{10}$Het, $-R^{10}$cycloalkyl, $-R^{10}$Ay, $-R^{10}$Het, $-R^{10}OR^9$, $-R^{10}C(O)R^9$, $-R^{10}$C(O)Ay, $-R^{10}$C(O)Het, $-R^{10}CO_2R^9$, $-R^{10}C(O)NR^9R^{11}$, $-R^{10}C(O)NR^7$Ay, $-R^{10}C(O)NHR^{10}$Het, $-R^{10}CH(OR^9)-R^{10}$; $-R^{10}CH(OR^9)$-Ay, $-R^{10}C(S)NR^9R^{11}$, $-R^{10}C(NH)NR^9R^{11}$, $-R^{10}SO_nR^9$, $-R^{10}SO_2NR^9R^{11}$, $-R^{10}SO_2NHCOR^9$, $-R^{10}NR^7R^8$, $-R^{10}NR^7$Ay, $-R^{10}NHC(NH)NR^9R^{11}$, cyano, nitro and azido; or

wherein when Y is CH, R^3 is not $-NR^7$Ay;

or a pharmaceutically acceptable salt thereof.

2. (Original) The compound according to claim 1 wherein each R^1 is the same or different and is independently selected from the group consisting of halo, alkyl, cycloalkyl, Ay, Het, $-OR^7$, $-C(O)R^9$, -C(O)Het, $-CO_2R^9$, $-C(O)NR^7R^8$, $-C(O)NR^7$Ay, $-C(O)NHR^{10}$Het, $-S(O)_nR^9$, $-S(O)_2NR^7R^8$, $-S(O)_2NR^7$Ay, $-NR^7R^8$, $-NR^7$Ay, -NHHet, $-NHR^{10}$Ay, $-NHR^{10}$Het, $-R^{10}$cycloalkyl, $-R^{10}$Het, $-R^{10}OR^9$, $-R^{10}C(O)NR^7$Ay, $-R^{10}SO_2NHCOR^9$, $-R^{10}NR^7R^8$, $-R^{10}NR^7$Ay, cyano, nitro and azido.

3. (Original) The compound according to claim 1 wherein each R^1 is the same or different and is independently selected from the group consisting of halo, Ay, Het, $-NR^7R^8$ and $-NR^7Ay$.

4. (Previously Presented) The compound according to claim 1 wherein p is 0 or 1.

5. (Previously Presented) The compound according to claim 1 wherein R^2 is selected from the group consisting of halo, alkenyl, cycloalkyl, cycloalkenyl, Ay, Het, $-OR^7$, -OAy, -OHet, $-OR^{10}Het$, $-S(O)_nR^9$, $-NR^7R^8$, -NHHet, $-NHR^{10}Het$, $-R^{10}NR^7R^8$ and $-R^{10}NR^7Ay$.

6. (Previously Presented) The compound according to claim 1 wherein R^2 is $-NR^7R^8$.

7-8. (Canceled.)

9. (Previously Presented) The compound according to claim 1 wherein R^3 and R^4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, Ay, $-OR^7$, $-CO_2R^7$, $-NR^7R^8$, $-R^{10}OR^7$ and $-R^{10}NR^7R^8$.

10. (Previously Presented) The compound according to claim 1 wherein R^3 and R^4 are both H.

11. (Previously Presented) The compound according to claim 1 wherein R^5 is selected from the group consisting of halo, alkyl, cycloalkyl, $-OR^7$, $-C(O)R^9$, -C(O)Ay, -C(O)Het, $-CH(OR^9)-R^{10}$, $-CH(OR^9)$-Ay, $-S(O)_nR^9$, $-S(O)_2NR^7R^8$, $-NR^7R^8$, $-NR^7Ay$, $-R^{10}$cycloalkyl, $-R^{10}Ay$, $-R^{10}Het$, $-R^{10}OR^9$, $-R^{10}C(O)R^9$, $-R^{10}SO_2NR^9R^{11}$ and $-R^{10}NR^7R^8$.

12. (Previously Presented) The compound according to claim 1, wherein R^5 is selected from the group consisting of alkyl, -C(O)Ay, $-CH(OR^9)$-Ay, $-R^{10}$cycloalkyl, $-R^{10}Ay$, $-R^{10}OR^9$ and $-R^{10}NR^7R^8$.

PU4959USw

13. (Previously Presented) A compound selected from the group consisting of:

2-Isobutyl-3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-*a*]pyridine;

2-Isobutyl-3-[2-(methylsulfinyl)pyrimidin-4-yl]pyrazolo[1,5-*a*]pyridine;

N-Cyclopentyl-4-(2-isobutylpyrazolo[1,5-*a*]pyridin-3-yl)pyrimidin-2-amine;

N-Cyclopentyl-4-[2-isobutyl-7-(methylthio)pyrazolo[1,5-*a*]pyridin-3-yl]pyrimidin-2-amine;

N-Cyclopentyl-4-[2-isobutyl-7-(methylsulfinyl)pyrazolo[1,5-*a*]pyridin-3-yl]pyrimidin-2-amine;

N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-isobutylpyrazolo[1,5-*a*]pyridin-7-amine;

2-(Diethoxymethyl)-3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-*a*]pyridine;

3-[2-(Methylthio)pyrimidin-4-yl]pyrazolo[1,5-*a*]pyridine-2-carbaldehyde;

{3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-*a*]pyridin-2-yl}(phenyl)methanol;

{3-[2-(Cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-*a*]pyridin-2-yl}(phenyl)methanol;

{3-[2-(Cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-*a*]pyridin-2-yl}(phenyl)methanone;

{7-(Cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-*a*]pyridin-2-yl}(phenyl)methanone;

4-(2-Benzylpyrazolo[1,5-*a*]pyridin-3-yl)-*N*-cyclopentyl-2-pyrimidinamine;

4-(2-Benzyl-7-chloropyrazolo[1,5-*a*]pyridin-3-yl)-*N*-cyclopentyl-2-pyrimidinamine;

N-{4-[2-Benzyl-7-(cyclopentylamino)pyrazolo[1,5-*a*]pyridin-3-yl]-2-pyrimidinyl}-*N*-cyclopentylamine;

N-Cyclopentyl-4-[2-(methoxymethyl)pyrazolo[1,5-*a*]pyridin-3-yl]-2-pyrimidinamine;

N-Cyclopentyl-4-[2-(methoxymethyl)-7-(methylsulfanyl)pyrazolo[1,5-*a*]pyridin-3-yl]-2-pyrimidinamine;

N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(methoxymethyl)pyrazolo[1,5-*a*]pyridin-7-amine;

N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(1-pyrrolidinyl)propyl]-pyrazolo[1,5-*a*]pyridin-7-amine;

N-({3-[2-(Methylsulfanyl)-4-pyrimidinyl]pyrazolo[1,5-*a*]pyridin-2-yl}methyl)-2-propanamine;

N-Cyclopentyl-4-{2-[(isopropylamino)methyl]pyrazolo[1,5-*a*]pyridin-3-yl}-2-pyrimidinamine;

N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[(isopropylamino)methyl]-pyrazolo[1,5-*a*]pyridin-7-amine;

4-{7-Chloro-2-[3-(isopropylamino)propyl]pyrazolo[1,5-*a*]pyridin-3-yl}-*N*-cyclopentyl-2-pyrimidinamine;

N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(isopropylamino)propyl]-pyrazolo[1,5-*a*]pyridin-7-amine;

4-{7-Chloro-2-[(2-methoxyethoxy)methyl]pyrazolo[1,5-a]pyridin-3-yl}-*N*-cyclopentyl-2-pyrimidinamine;

3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-[(2-methoxyethoxy)methyl]-N-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-7-amine;

N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[(2-methoxyethoxy)-methyl]pyrazolo[1,5-*a*]pyridin-7-amine;

N-Cyclopentyl-4-(2-isopropylpyrazolo[1,5-*a*]pyridin-3-yl)pyrimidin-2-amine;

N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-isopropylpyrazolo[1,5-a]pyridin-7-amine;

2-Cyclopropyl-3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-*a*]pyridine;

N-Cyclopentyl-4-(2-cyclopropylpyrazolo[1,5-*a*]pyridin-3-yl)pyrimidin-2-amine; and

N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-cyclopropylpyrazolo[1,5-*a*]pyridin-7-amine;

or a pharmaceutically acceptable salt thereof.

14. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1.

15. (Original) The pharmaceutical composition according to claim 14 further comprising a pharmaceutically acceptable carrier or diluent.

16. (Previously Presented) The pharmaceutical composition according to claim 14, further comprising an antiviral agent selected from the group consisting of aciclovir and valaciclovir or a pharmaceutically acceptable salt thereof.

17. (Previously Presented) A method for the treatment of a herpes viral infection selected from herpes simplex virus 1 and herpes simplex virus 2 in an animal, said method comprising administering to the animal a therapeutically effective amount of a compound according to claim 1.

18. (Canceled.)

19. (Previously Presented) A method for the treatment of a condition or disease associated with a herpes viral infection selected from herpes simplex virus 1 and herpes simplex virus 2 in an animal, comprising administering to the animal a therapeutically effective amount of a compound according to claim 1.

20. (Currently Amended) A process for preparing a compound according to claim 1 wherein R^2 is selected from $-NR^7R^8$, Het, $-NHR^{10}$Het and –NHHet and R^3 and R^4 are the same or different and are each independently H or alkyl, said process comprising the steps of:

a) coupling a compound of formula (II):



II

wherein X is chloro, bromo, iodo or triflate;

R^2 is selected from $-NR^7R^8$, Het, $-NHR^{10}$Het and –NHHet and

R^3 and R^4 are the same or different and are each independently H or alkyl;

to a terminal alkyne of formula (III):



III

to prepare a compound of formula (IV):



IV

and

b) reacting an *N*-amino pyridinium salt of formula (V):



V

wherein Z- is a counterion;

with the compound of the formula (IV) to prepare a compound of formula (I).

21-28. (Canceled.)